- Home
- NTIP vs BOLT Comparison
NTIP vs BOLT Comparison
Compare NTIP & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | BOLT |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.0M | 11.5M |
| IPO Year | 1998 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NTIP | BOLT |
|---|---|---|
| Price | $1.45 | $5.43 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $34.00 |
| AVG Volume (30 Days) | 9.4K | ★ 32.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 7.35% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $150,000.00 | ★ $5,195,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.16 | $4.41 |
| 52 Week High | $1.90 | $12.60 |
Technical Indicators
Market Signals| Indicator | NTIP | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 42.71 | 53.68 |
| Support Level | $1.37 | $5.18 |
| Resistance Level | $1.46 | $5.98 |
| Average True Range (ATR) | 0.10 | 0.34 |
| MACD | -0.00 | 0.10 |
| Stochastic Oscillator | 26.09 | 52.23 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.